Skip to main content
. Author manuscript; available in PMC: 2023 Jul 5.
Published in final edited form as: J Am Coll Cardiol. 2022 Jul 5;80(1):36–46. doi: 10.1016/j.jacc.2022.04.039

Figure 2. Cumulative incidence for SCA/VA and MACE, overall and by HF history.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

A. SCA/VA outcome in the overall population

B. MACE outcome in the overall population

C. SCA/VA outcome in the subgroup with history of HF

D. MACE outcome in the subgroup with history of HF

E. SCA/VA outcome in the subgroup without history of HF

F. MACE outcome in the subgroup without history of HF

Kaplan-Meier plots of cumulative incidence for SCA/VA and MACE comparing 1:1 PS-matched hydroxychloroquine vs. methotrexate initiators overall and by history of HF.

Incidence rates between treatment groups are compared with log-rank tests.

ABBREVIATIONS: SCA/VA, sudden cardiac arrest and ventricular arrythmia; MACE, 3-point major adverse cardiac events (i.e., myocardial infarction, stroke, and cardiovascular mortality); HF, heart failure.